Next-Generation Induced Proximity Modulators

Innovative Chemistries and Assays for Driving Covalent and Proximity-Triggered Interactions

April 19, 2027 ALL TIMES PDT

Chemically-induced proximity is an emerging strategy for developing new therapies, and covalent chemistries are often being leveraged to trigger proximity-driven degradation, stabilization, localization, folding, post-translational modifications (PTMs) or disruption of protein-protein interactions. Cambridge Healthtech Instituteâ€™s symposium on Next-Generation Induced Proximity Modulators brings together academic and industry scientists from medicinal chemistry, chemical biology, assay development, proteomics, and more to discuss innovative chemistries and technologies for leveraging proximity-driven therapeutic intervention. This symposium is a precursor to what will be discussed in the conferences on Degraders and Glues, and Protein-Protein Interactions that follow.

Preliminary Agenda

PROXIMITY-DRIVEN THERAPIES

Chairperson's Remarks

Daniel A. Erlanson, PhD, Chief Innovation Officer, Frontier Medicines Corporation , Chief Innovation Officer , Frontier Medicines Corporation

FEATURED PRESENTATION: Expanding the Druggable Proteome by Rewiring Cellular Circuitries with TCIPs and SCIPs

Photo of Gerald Crabtree, MD, David Korn Professor of Experimental Pathology & Developmental Biology, Stanford University , David Korn Professor , Experimental Pathology & Developmental Biology , Stanford University — Gerald Crabtree, MD, David Korn Professor of Experimental Pathology & Developmental Biology, Stanford University , David Korn Professor , Experimental Pathology & Developmental Biology , Stanford University

Interrogating the Druggable Proteome with Proximity Pharmacology

Photo of Fleur Ferguson, PhD, Assistant Professor of Chemistry and Biochemistry, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego , Assistant Professor , Chemistry and Biochemistry , University of California, San Diego — Fleur Ferguson, PhD, Assistant Professor of Chemistry and Biochemistry, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego , Assistant Professor , Chemistry and Biochemistry , University of California, San Diego

Proximity-Driven Functional Screening Platform for the Discovery of Non-Inhibitory Ligands for Deubiquitinating Enzymes

Photo of Weijun Gui, PhD, Assistant Professor, Chemistry, Syracuse University , Assistant Professor , Chemistry , Syracuse University — Weijun Gui, PhD, Assistant Professor, Chemistry, Syracuse University , Assistant Professor , Chemistry , Syracuse University

Targeted protein stabilization using deubiquitinase-targeting chimeras (DUBTACs) is a promising therapeutic strategy, but its development is limited by the scarcity of non-inhibitory deubiquitinase (DUB) ligands. My lab developed a proximity-driven, on-bead functional screening platform to discover these ligands. Using this approach, we identified a novel USP7 ligand and developed WJ045, a DUBTAC that robustly increased CFTR protein levels in cells, demonstrating the platformâ€™s potential for targeted protein stabilization.

When Proteins Adapt: Harnessing Induced Conformations for Molecular Glue Discovery

Photo of Andres Hernandez de la PeÃ±a, PhD, Associate Principal Scientist, Neomorph Inc. , Associate Principal Scientist , Neomorph Inc. — Andres Hernandez de la PeÃ±a, PhD, Associate Principal Scientist, Neomorph Inc. , Associate Principal Scientist , Neomorph Inc.

BRAINSTORMING SESSION

Discussion on Therapeutic Impact & Clinical Success of Proximity Inducers

For more details on the conference, please contact:
Tanuja Koppal, PhD
Senior Conference Director
Cambridge Healthtech Institute
Email: tkoppal@healthtech.com

For sponsorship information, please contact:
Kristin Skahan
Senior Business Development Manager
Cambridge Healthtech Institute
Phone: (+1) 781-972-5431
Email: kskahan@healthtech.com

APRIL 19

APRIL 20 - 21

APRIL 21 - 22

View All Sponsors

View All Media Partners